Luyi S Sen

US Patent:

6593130, Jul 15, 2003

Filed:

Apr 14, 2000

Appl. No.:

09/549904

Inventors:

Luyi Sen - Stevenson Ranch CA
Guanggen Cui - Stevenson Ranch CA
Jack W. Judy - Los Angeles CA
Hillel Laks - Beverly Hills CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C12M 142

US Classification:

4352852, 4351735, 604 21

Abstract:

An array is placed in contact with or close proximity with an organ or tissue surface to cause electroporation for gene, protein, drug delivery in both ex vivo and in vivo applications. A low DC voltage with a short pulse duration, and long burst pulse is applied to the array. A long rest period is provided between pulse bursts to allow for cell recovery. To enable the application of a low voltage shock in a large organ with same transfection efficiency, four gene, protein and drug delivery systems are illustrated.

US Patent:

6738655, May 18, 2004

Filed:

Oct 3, 2001

Appl. No.:

09/958452

Inventors:

Luyi Sen - Stevenson Ranch CA
Guanggen Cui - Stevenson Ranch CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61B 504

US Classification:

600374, 600509, 607122

Abstract:

A catheter-delivered electrode array is used to three dimensionally map the endomyocardial monophasic action potential (MAP). The catheter is used in a method for endomyocardial MAP mapping and for establishing diagnostic criteria for the cardiac myocyte injury. During allograft rejection, conduction impairment occurs within the atrial myocardium. Abnormalities of the terminal force of the P wave in Lead V1 (ptfV1) and dispersion of corrected atrial repolarization (Ta-TcD) represent interatrial conduction defects that accompanies the rejection process. Three dimensional endomyocardium monophasic action potential mappings are used to directly monitor the pathophysiological changes in cardiac myocytes. Changes in amplitude, duration and morphology of the action potential were recorded and used to detect the early rejection of the transplant organ with high sensitivity and specificity. Using this MAP-mapping system, the area of myocardium injury induced by a coronary artery occlusion or by ablation can be pin pointed.

US Patent:

7697981, Apr 13, 2010

Filed:

Mar 24, 2003

Appl. No.:

10/508730

Inventors:

Luyi Sen - Stevenson Ranch CA, US
Guanggen Cui - Stevenson Ranch CA, US
Hillel Laks - Beverly Hills CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61N 1/00

US Classification:

607 2

Abstract:

An electromagnetic field is applied to transplanted cells during their transplantation culturing to achieve confluence and alignment of transplanted cells into damaged tissue and organs, therefore improving the synchronization of electrical and mechanical tissue or organ functions. The electromagnetic field may be applied by catheter based devices to a selected portion of tissue or to the entire surface of a hollow body cavity or organ, such as a heart chamber. The electromagnetic field is provided by an expansible net or array from a catheter or on an inflatable balloon or stent. The electromagnetic field is also provided by an implantable net or array of electrodes which may either be hardwired to a pulse generator or coupled by means of wireless or inductive transmission.

US Patent:

20080182251, Jul 31, 2008

Filed:

Mar 16, 2006

Appl. No.:

11/909074

Inventors:

Luyi Sen - Stevenson Ranch CA, US
Guangen Cui - Stevenson Ranch CA, US

International Classification:

C12N 15/01
C12M 1/42
C12Q 1/68
C12Q 1/02

US Classification:

435 6, 435446, 4352852, 435 29

Abstract:

Ex vivo gene, protein or drug delivery to macroscopic quantities of various types of cells, cell clusters, or tissues using ultra low strength LSEFN strategies is disclosed in which the bioengineered cells and tissues are then systemically transfused, delivered or implanted into the various organs or tissue for the treatment of diseases. An LSEFN chamber is used which is shaped and sized to intimately contain the cells, cell clusters, or tissues in a transfusion chamber between opposing membrane encapsulated electrode arrays across which LSEFN pulses are applied.

US Patent:

20090169474, Jul 2, 2009

Filed:

Mar 20, 2007

Appl. No.:

12/280680

Inventors:

Luyi Sen - Stevenson Ranch CA, US
Sanjiv S. Gambhir - Portola Valley CA, US

Assignee:

The Regentsf of the University of California - Oakland CA

International Classification:

A61K 51/06
C12Q 1/68
A61K 49/04

US Classification:

424 173, 435 6, 424 94

Abstract:

An composition in a method for noninvasively monitoring the expression of therapeutic transgene delivered ex vivo and in vivo for the treatment of diseases includes the step of quantitatively imaging a reporter gene expression which is coupled to a therapeutic gene on a plasmid vector to infer levels, location, or duration of the therapeutic gene expression in the targeted tissues or organs. The reporter gene is imaged using a radiopharmaceutical for scintigraphic imaging of the gene expression interactions with the reporter gene, namely positron emission tomography, gamma camera or single-photon emission computed tomography. The genes are delivered with a liposome encapsulated reporter-therapeutic linked transgene vector with balanced reporter/therapeutic transgene expression. A transgene composition includes the reporter gene linked to the therapeutic gene or genes incorporated in and delivered by a liposome encapsulated reporter-therapeutic linked transgene vector.

US Patent:

20090264809, Oct 22, 2009

Filed:

Apr 2, 2007

Appl. No.:

12/294313

Inventors:

Luyi Sen - Stevenson Ranch CA, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

International Classification:

A61N 1/30

US Classification:

604 20

Abstract:

The illustrated embodiments of the invention include four preferred embodiments: 1) a method and apparatus for the joint and its related soft tissue for bone gene, protein and drug delivery; 2) a method and apparatus for gene, protein and drug delivery to an extremity; 3) a method and apparatus for delivery of gene, protein and drug delivery to skin and soft tissue; and/or 4) a method and apparatus for delivery of a gene, protein and drug to soft tissue tumor.

US Patent:

20100004584, Jan 7, 2010

Filed:

Jan 2, 2008

Appl. No.:

12/519509

Inventors:

Luyi Sen - Stevenson Ranch CA, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

International Classification:

A61N 1/30

US Classification:

604 20

Abstract:

An apparatus for in vivo intracellular transfection of gene, siRNA, shRNA vectors, and other biomedical diagnostic and therapeutic drugs and molecules for the treatment of arthritis and other orthopedic diseases in large animals and humans includes: a source of low voltage, short duration pulses in long duration bursts (LSEN); an electrode mesh system coupled to the source for generating distributed electric field network into a joint, including bones, cartilages, and related tissues; and means for transfecting the gene, siRNA, shRNA vectors, and other biomedical diagnostic and therapeutic drugs and molecules into a joint. The electrode mesh system includes alternatively arranged negative and positive electrodes in a first array which is capable of being inserted into a joint cavity, and either an alternatively arranged negative and positive or an all negative second electrode array which is positioned outside of the joint and in directly contact with overlying skin.

US Patent:

20100111983, May 6, 2010

Filed:

Mar 12, 2008

Appl. No.:

12/531291

Inventors:

Luyi Sen - Stevenson Ranch CA, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

International Classification:

A61K 39/00
A01N 1/00
C12N 13/00
C12M 1/00

US Classification:

4241841, 435 11, 4351731, 4352831

Abstract:

Application to an allograft or xenograft of a low strength electric field network (LSEN) together with an immuno-suppressive drug, gene and siRNA or other gene-based therapy is used to mediate the immune responses within an donor organ, tissue or cells, to prevent the acute and chronic rejection and to induce true tolerance, The gene(s) is locally transferred ex vivo in the time interval between harvest and implantation of allografts or xenografts before the implantation to introduce the long-term over expression of immunosuppressive and/or modulative molecules, or for down regulating alloreactive molecules in the donor organ, tissue or cells only and not in the recipient's whole body system.